Skip to main content
Evidence: BAnti-InflammatoryNeuroprotection

VIP: Benefits, Dosage & FDA Status

Vasoactive Intestinal Peptide

A 28-amino-acid neuropeptide with broad immunomodulatory effects. Used clinically (intranasal) by some practitioners for chronic inflammatory response syndrome (CIRS).

FDA Status

Not FDA-approved — investigational; ongoing trials for sarcoidosis

Typical Dose

50 mcg intranasal, 4 times daily (CIRS protocols)

Evidence Grade

BLimited clinical + robust preclinical evidence

Half-Life

~2 minutes (parenteral); local intranasal half-life longer

Routes of Administration

intranasal, intravenous

First Synthesized

1970

Clinics Indexed

24 providers have offered VIP in our tracked directory.

Mechanism of Action

Activates VPAC1/VPAC2 receptors; broadly anti-inflammatory and bronchodilatory.

Key Reported Benefits

Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade B indicates limited clinical + robust preclinical evidence.

Reported Side Effects

  • Hypotension at high doses
  • Flushing

Contraindications

  • Severe hypotension
  • Pregnancy

Regulatory & Safety Context

FDA status: Not FDA-approved — investigational; ongoing trials for sarcoidosis

This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.

See state-by-state legality: US peptide legality by state →

References

Selected primary literature on VIP. Full PubMed records linked. Additional citations are available on request.

  1. PubMed PMID 20176046

Last reviewed: 2026-04-30

← Back to all peptides